Aralez Bio

Proprietary enzymatic and biocatalysis technology.

About

Aralez Bio is leveraging Nobel Prize winning technology from Caltech for biosynthesis of non-canonical Amino Acids for use in biologic medicines such as GLP-1 agonists. Aralez’s technology surpasses existing chemical synthesis methods across the board – more variety, better scale-ability, lower cost, and no toxic byproducts.

  • Location: San Francisco, CA
  • Paladin Initial Investment Date: August 2024

Portfolio Stats

Over 75 Companies

Paladin has invested in over 75 portfolio companies since 2001.

4 Continents

Paladin has invested in companies in North America, Australia, Europe, and South America.

Over $2 billion

Paladin was founded in 2001 and has since managed over $2B of companies and assets.